Reproductive system neoplasm

This trial tests whether combining two drugs—pucotenlimab, which helps the immune system attack cancer, and becotatug vedotin, which delivers a toxin directly to tumor cells—can eliminate advanced penile cancer before surgery. Men with high-risk, locally advanced penile squamous …

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…

This trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…

This trial tests whether a single, outpatient treatment using low-thermal argon plasma can clear grade 2 cervical intraepithelial neoplasia (CIN2), a precancerous condition. Participants receive either the plasma treatment, a sham procedure, or standard active surveillance. The m…

This phase 2 trial is testing whether the immunotherapy drug sintilimab can eliminate early-stage (I-II) MSI-H/dMMR endometrial cancer without the need for surgery. About 48 participants will receive sintilimab alone every three weeks. The goal is to see if the drug can produce a…

This trial is testing whether a personalized cell therapy can help women with ovarian cancer that has returned. Doctors will remove a tumor, extract immune cells called tumor-infiltrating lymphocytes (TILs), and boost them in the lab before infusing them back into the patient. Af…

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This phase II trial is testing an investigational drug called BL-M09D1 in people with advanced gynecological cancers (such as ovarian, cervical, or endometrial cancer) and other solid tumors that have progressed despite standard treatment. The drug is given by intravenous infusio…

This trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This Phase II trial tests whether an immune-boosting drug (N-803) alone or combined with a vaccine (ETBX-071) can lower PSA levels in men whose prostate cancer has returned after targeted radiation therapy. Participants receive up to eight cycles of treatment and are followed for…

This trial tests whether the LapBox Manual Containment System, a double-wall bag used during laparoscopic surgery, can prevent leaks when removing uterine fibroids. About 30 women having laparoscopic hysterectomy or myomectomy will use the device, and surgeons will check for any …

This trial is testing a new way to deliver radiation therapy for prostate cancer. Instead of standard radiation, it uses MRI to precisely target the tumor, potentially sparing healthy tissue and reducing side effects. The study will include about 20 adults with early-stage prosta…

This Phase 3 trial tests a new biologic drug (PF-08634404) plus chemotherapy against the approved drug Keytruda plus chemotherapy in 600 women with advanced or recurrent pMMR endometrial cancer. The goal is to see if the new combination helps patients live longer without their ca…

This trial tests whether a supervised strength and conditioning program can protect the heart and reduce inflammation in men with prostate cancer who are receiving radiation and hormone therapy. Participants will follow a structured exercise routine, and researchers will measure …

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …

This phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-…

This phase 2 trial is testing an experimental drug called xaluritamig in men with metastatic castrate-resistant prostate cancer who had only a partial or stable response to lutetium-177 therapy. The goal is to see if xaluritamig can shrink tumors or lower PSA levels. About 30 par…

This phase 2 trial is testing whether adding relacorilant—a drug that blocks a stress-related hormone—to the chemotherapy nab-paclitaxel can shrink tumors in people with recurrent or metastatic cervical cancer. Participants have already tried platinum-based chemo and immunotherap…

This study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with Grade Group 3 intermediate-risk prostate cancer. Fifty participants will receive the treatment and be followed for two years to see if the cancer is reduced and t…

This trial is testing whether a new drug called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer and delay cancer growth compared to standard chemotherapy. The study includes adults with high-grade serous or…

This early-phase trial is testing whether combining two immune-based treatments—Sipuleucel-T, a vaccine made from a patient's own immune cells, and N-803, a drug that boosts immune activity—is safe and tolerable for men with metastatic prostate cancer that has stopped responding …

This trial tests whether adding a chemical injection to microwave ablation improves treatment for uterine fibroids, common non-cancerous tumors that can cause heavy bleeding and pain. Microwave ablation uses heat to destroy fibroid tissue, but blood flow can cool the area and red…

This trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostat…

This phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…

This study tests whether adding a radioactive drug called 177Lu-PSMA-617 to standard radiation therapy can allow men with high-risk localized prostate cancer to take hormone therapy for only 6 months instead of the usual 24 months. The goal is to see if this approach is as effect…

This early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…

This phase 3 trial tests whether the experimental drug mocertatug rezetecan (Mo-Rez), given alone or with bevacizumab, can delay cancer progression better than standard observation or bevacizumab alone in people with newly diagnosed advanced ovarian cancer that does not have a ho…

This early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This trial tests the drug mercaptopurine in people with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic condition that raises the risk of skin, uterine, and kidney tumors. The study aims to find the safest dose and see if the drug can shrink kidney canc…

This early-stage trial is testing an experimental drug called JNJ-98768111 in people with advanced prostate cancer that has spread to other parts of the body. The drug is designed to seek out and attach to a protein called KLK2 on prostate cancer cells, delivering a toxic agent d…

This trial tests whether injecting a diluted solution of terlipressin, a drug that narrows blood vessels, under the outer layer of a uterine fibroid before removal can reduce blood loss during myomectomy surgery. Women scheduled for myomectomy will be randomly assigned to receive…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This study offers continued access to an experimental combination of two oral drugs—avutometinib and defactinib—for people with recurrent low-grade serous ovarian cancer (LGSOC) who have already been benefiting from this treatment in a prior study. The goal is to allow uninterrup…

This study tests an experimental drug called TUB-040 in people with recurrent or progressive endometrial cancer that has not responded to platinum-based chemotherapy and immunotherapy. TUB-040 is an antibody-drug conjugate designed to bind to a protein called NaPi2B on cancer cel…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This study compares a robotic water-jet procedure called Aquablation to active surveillance (close monitoring) in 333 men with low- or intermediate-risk localized prostate cancer. The goal is to see if Aquablation can better prevent cancer from progressing to a more serious grade…

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This phase 2 trial is testing whether combining two drugs—mirvetuximab soravtansine and suvemcitug—can help people with a type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 20 adults with FRα-positive, platinum-resistant recur…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This trial is testing whether adding elemene liposomes—a compound derived from a traditional Chinese medicinal plant—to standard chemotherapy (carboplatin and paclitaxel) can help people with advanced or recurrent endometrial cancer. Participants will receive either the combinati…

This phase 2 trial is testing whether adding an experimental drug called OK-1 to the standard chemotherapy paclitaxel can shrink tumors in people with advanced or recurrent endometrial cancer. Participants take OK-1 capsules twice daily along with weekly intravenous paclitaxel. T…

This early-stage trial is testing an experimental drug called SHR-6914 in men with prostate cancer that has spread to other parts of the body. The main goal is to see if the drug is safe and tolerable, and to find the right dose for future studies. Participants must have a confir…

This trial is testing whether using microultrasound to guide a radiation boost to cancerous spots inside the prostate can reduce side effects compared to standard radiation therapy. Men with intermediate-risk prostate cancer will receive stereotactic body radiation therapy (SBRT)…

This trial tests whether adding darolutamide to standard chemotherapy and hormone therapy before prostate removal can improve long-term outcomes for men with locally advanced prostate cancer. Participants receive either the triple combination or the standard two-drug regimen for …

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This trial is investigating whether an experimental drug called XNW5004, when combined with standard anti-tumor therapies, can help control advanced prostate cancer. The study involves men with prostate cancer that has spread. Researchers are looking at how safe the combination i…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This trial explores whether semaglutide, a drug approved for weight management, can affect tumor biology when given for 3 to 6 months before prostate removal surgery. About 20 men with intermediate-risk localized prostate cancer and a BMI over 35 will receive weekly injections. R…

This study tracks the safety and effectiveness of mirvetuximab soravtansine (MIRV), a drug that targets a protein called folate receptor alpha on cancer cells, in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers will observe 400 patients r…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This early-phase trial explores whether PSMA PET scans can help doctors adjust radiation therapy for men with prostate cancer that has spread to 4 to 20 spots in the body. Participants receive standard hormone therapy plus a special PET scan, then targeted radiation to all visibl…

This study tests a new drug combination (BL-B01D1 plus other treatments) in 180 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can delay cancer growth or shrink tumors. Part…

Hormone therapy for prostate cancer often causes muscle loss, which may weaken the immune system by reducing a key signalling protein called IL-7. This trial tests whether a 12-week supervised strength training programme can prevent muscle loss and raise IL-7 levels in men receiv…

This trial tests whether an online, personalized lifestyle program can help rural postmenopausal breast and endometrial cancer survivors lose weight and improve their health. Participants follow a tailored diet and aerobic exercise plan, with mobile health tools to track progress…

This trial tests whether a single injection of carbetocin, a longer-acting relative of oxytocin, can reduce blood loss in women undergoing open abdominal surgery to remove uterine fibroids. About 900 participants will be randomly assigned to receive carbetocin or a placebo, and d…

This early-phase trial is testing whether a personalized mRNA vaccine called NeoOVSV, given alongside standard chemotherapy and an immunotherapy drug, can safely help prevent ovarian cancer from returning after surgery. The vaccine is designed to train the immune system to recogn…

This phase 2 trial is testing whether a targeted antibody-drug conjugate called sacituzumab tirumotecan, given alone or together with the immunotherapy pembrolizumab, can shrink tumors in people with ovarian clear cell carcinoma that has returned after prior immunotherapy. The st…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…

This study looks at how effective the drug Pluvicto (177Lu-PSMA-617) is in treating men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. Researchers will analyze medical records from over 1,000 patients …

This phase II pilot trial is testing a three-drug combination—radium-223, darolutamide, and standard hormone therapy—in men with high-volume metastatic hormone-sensitive prostate cancer. The goal is to see if adding radium-223 as maintenance therapy after initial treatment can im…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…

This phase II trial tests an experimental drug called SYS6041, alone or combined with chemotherapy and other agents, in women whose ovarian cancer has returned. The study evaluates safety, the best dose, and how well the treatments shrink tumors. Participants must have a specific…

This study tests an experimental injection called BBM-C101 in 200 people with persistent HPV16 or HPV18 infection and low-grade precancerous lesions of the cervix, vulva, vagina, or anus. Participants receive four shots under the skin over three weeks. The trial monitors safety a…

This trial tests whether adding orlistat, a weight-loss drug that blocks fat absorption, to standard progestin therapy can improve treatment response in young women (45 or younger) with early-stage endometrial cancer or atypical endometrial hyperplasia who have low progesterone r…

This study tests an experimental biologic, NWRD09, in women aged 18 to 65 with HPV16-positive cervical high-grade squamous intraepithelial lesions (HSIL), a precancerous condition. Participants receive four intramuscular injections over 12 weeks. The main goal is to see if the tr…

This study tests whether adding the experimental drug saruparib to standard hormone therapy can slow the growth of metastatic hormone-sensitive prostate cancer. It includes men whose cancer has not progressed after prior chemotherapy or a specific type of radiation therapy. Parti…

This study explores whether a simple blood test that measures tumor DNA (ctDNA) can help doctors decide when to stop a targeted radiation therapy called 177Lu-PSMA-617 in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The goal is…

This trial tests a streamlined approach for men at high risk of clinically significant prostate cancer. Under one anesthesia session, doctors perform an MRI-guided biopsy, analyze the tissue immediately with rapid lab tests, and if cancer is confirmed, proceed directly to laparos…

This trial tests a 24-week virtual care program called BRIDGE NET for people with serious mental illness who are starting cancer treatment. The program brings together oncology and mental health teams to plan care, provide early psychiatric support, and regularly check in with pa…

This phase III trial compares a shorter course of radiation therapy (hypofractionated) against the standard longer course for people with cervical cancer. Both groups also receive chemotherapy and brachytherapy. The goal is to see if the shorter schedule controls the cancer just …

This phase 3 trial tests an experimental drug called SYS6043 against standard chemotherapy in people with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. Participants are randomly assigned to receive either SYS6043 or one of three standard chemotherapies…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This phase 3 trial tests whether a new drug called mocertatug rezetecan (Mo-Rez) combined with bevacizumab works better than standard chemotherapy plus bevacizumab for women with platinum-sensitive ovarian cancer. The study includes about 690 participants whose cancer has returne…

This phase 3 trial tests whether adding an experimental drug (GSK5733584) to standard immunotherapy can help keep advanced or recurrent endometrial cancer from growing. About 610 adults who have already completed initial chemotherapy with immunotherapy will receive either the new…

This trial tests an experimental vaccine called SYS6026 in people with high-grade cervical lesions caused by HPV type 16 or 18. The goal is to see if the vaccine can help the body clear the virus and reverse the lesions, potentially avoiding the need for surgery. Participants are…

This study tests whether a 12-week virtual cooking and nutrition program is practical and helpful for Hispanic prostate cancer survivors and their caregivers. Participants attend nutrition education, cooking classes, and health coaching sessions online. The goal is to see if the …

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This study tests whether a daily oral supplement containing green tea extract (EGCG), folic acid, vitamin B12, and hyaluronic acid can help women clear a persistent human papillomavirus (HPV) infection. HPV is a common virus that can cause cervical cancer if it stays in the body …

This trial investigates whether a minimally invasive procedure using a special dye can better detect cancer spread in men with early-stage testicular cancer. About 20-30% of these patients have cancer cells in lymph nodes that standard scans miss. Participants are randomly assign…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This study looks at how well the chemotherapy drug temozolomide works for people with aggressive pituitary tumors or pituitary cancer that hasn't responded to standard treatments like surgery or radiation. Researchers are collecting data from medical records across multiple hospi…

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tum…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …

This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…

This study tests a new approach for treating high-grade cervical precancer (HSIL) using a cream called HAL that is activated by a special light, instead of standard surgery. About 230 women will be randomly assigned to receive either the light therapy or surgery. The main goal is…

This phase II trial compares a new two-drug combination (sacituzumab govitecan plus bevacizumab) against standard chemotherapy (carboplatin, liposomal doxorubicin, and bevacizumab) in 87 women with platinum-sensitive ovarian cancer that has progressed after PARP inhibitor mainten…

This study monitors the safety and effectiveness of mirvetuximab soravtansine (MIRV) in people with a specific type of ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy and tests positive for the folate receptor-alpha…

This study tests an experimental drug, TAX2, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in more people. Researchers will monitor side effects, h…

This phase II trial tests a combination of two drugs—SYS6026 and Enlonstobart—in people with advanced solid tumors that have spread and are linked to HPV types 16 or 18. The study aims to see if the combination is safe and shows signs of shrinking tumors. Participants must be at …

This trial tests whether a special mesh-like suture (Duramesh) can prevent incisional hernias better than a standard slowly-absorbable suture (PDS loop) in women having abdominal surgery for gynecological cancers. About 300 participants will be randomly assigned to one of the two…

This phase 1 trial tests whether giving a higher first dose of the radioactive drug Lu-177-PSMA-617 can improve treatment for men with metastatic castration-resistant prostate cancer. The drug targets a protein on prostate cancer cells and delivers radiation to kill them. Researc…

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This early-stage trial tests whether adding CP-PCA07 (a form of niclosamide, a drug used for tapeworm infections) to the standard drug enzalutamide can safely help men with castration-resistant prostate cancer that has stopped responding to treatment. The study involves 18 men an…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This trial tests whether combining an immune-boosting cream (imiquimod) with a low dose of an immunotherapy drug (nivolumab) can shrink vulvar squamous cell carcinoma tumors before surgery. About 50 women with resectable, early-to-moderate stage vulvar cancer will receive the dru…

This trial investigates whether combining a targeted radioactive drug (177Lu-PSMA-617) with a hormone therapy (darolutamide) before surgery can improve outcomes for men with high-risk localized prostate cancer. Participants receive two doses of the radioactive drug and daily horm…

This trial explores whether a new type of radiotherapy called CT online-adaptive radiotherapy can safely deliver treatment for endometrial cancer in just 5 sessions over a week and a half, instead of the usual 25 sessions over 5 weeks. The study includes 30 adults who have had su…

This trial tests a drug called sacituzumab govitecan in people with advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancer that has high levels of a protein called TROP-2. Participants must have already tried standard treatments without success. The drug is g…

This trial tests a personalized mRNA vaccine called NeoOVIV in people with stage II or III ovarian cancer who have had surgery. The vaccine is designed to teach the immune system to recognize and attack cancer cells. Participants receive the vaccine alongside standard chemotherap…

This phase 2 trial tests a drug called tisotumab vedotin in people with advanced squamous cell carcinoma of the vulva that has returned or spread. The drug is an antibody-drug conjugate designed to seek out and destroy cancer cells. The study aims to see how many participants' tu…

This Phase 3 trial compares a new drug called BL-M07D1 against standard chemotherapy in 404 people with HER2-expressing ovarian, fallopian tube, or peritoneal cancer that has become resistant to platinum-based treatment. Participants will receive either BL-M07D1 or one of several…

This phase 2 trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery can improve outcomes for people with advanced ovarian cancer. Participants receive 3-4 cycles of the combination, followed by surgery to rem…

This study looks at how well darolutamide (Nubeqa) plus standard hormone therapy works in Chinese men whose prostate cancer has become resistant to earlier treatment but hasn't spread. About 800 men will take part, and researchers will track PSA levels to see if the cancer is con…

This early-stage trial tests an injection called BBM-C101 in 60 women with high-grade cervical precancer linked to HPV16 or HPV18. The goal is to see if the drug is safe and can shrink or eliminate abnormal cells, potentially offering a non-surgical alternative. Participants rece…

This study tests whether a combination of two immunotherapy drugs (QL1706), a targeted therapy (bevacizumab), and standard chemotherapy can shrink advanced ovarian cancer before surgery. About 36 women with stage III-IV ovarian cancer will receive the treatment every 3 weeks, the…

This study tests a new oral drug called DAT-2645 in up to 30 people with advanced or metastatic ovarian cancer that has a BRCA1/2 mutation or is HRD-positive. Participants take the drug daily in 21-day cycles. The main goal is to see if the drug shrinks tumors, and researchers wi…

This early-phase trial tests a one-time treatment called OPB-201, where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called PRAME. The study will enroll 30 adults with recurrent endometrial cancer or platinum-…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This study tests a new drug called DEC003M, which is designed to seek out and destroy prostate cancer cells by targeting a protein called PSMA. The trial enrolls adults with advanced prostate cancer that has stopped responding to standard hormone therapy. Researchers aim to find …

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This study tests a personalized approach to hormone therapy for men with metastatic hormone-sensitive prostate cancer. The goal is to reduce treatment intensity for lower-risk patients to minimize side effects while still controlling the cancer. About 108 participants will receiv…

This early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…

This study looks at how well a combination of two drugs, iparomlimab and tuvonralimab (called QL1706), works for people with recurrent or metastatic cervical cancer that has worsened after platinum-based chemotherapy. Researchers will compare outcomes of those receiving QL1706 to…

This phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…

This study tests the safety of the immunotherapy drug dostarlimab when given together with standard chemotherapy (carboplatin and paclitaxel) as a first treatment for adults in India with advanced or recurrent endometrial cancer. Participants receive the drug combination initiall…

This study tests whether adding precisely targeted radiation to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer. All participants first receive six months of darolutamide plus androgen deprivation therapy. Those whose cancer has not progressed…

This trial tests whether fluzoparib plus bevacizumab works as well as the standard olaparib plus bevacizumab for maintenance therapy in women with HRD-positive advanced ovarian cancer after initial chemotherapy. The study enrolls about 120 participants and tracks how long they st…

This Phase II trial tests whether adding the immunotherapy drug cadonilimab to chemotherapy before surgery helps people with locally advanced cervical cancer live longer without the disease coming back. About 134 participants will be randomly assigned to receive either the drug c…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This study tests whether a single, powerful dose of MRI-guided radiation can safely treat prostate cancer that has come back in a few lymph nodes after initial treatment. Forty-eight men will receive one 24 Gy radiation session aimed precisely at the affected nodes. The main goal…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This phase 2 trial tests a radioactive drug called terbium-161 PSMA in 60 men with metastatic prostate cancer that has worsened after standard treatments. The drug is designed to seek out and destroy cancer cells. Participants will receive three cycles of the drug, and researcher…

This study tests whether giving radiotherapy to the prostate and to cancer spots seen on PET scans can help men with metastatic prostate cancer whose PSA levels remain high after six months of hormone therapy. Participants continue their hormone treatment and receive three PSMA-P…

This study tests whether tamoxifen, a drug commonly used for breast cancer, can speed up testosterone recovery in men with prostate cancer who have completed hormone therapy (ADT). Many men experience low testosterone for months or years after stopping ADT, causing fatigue, depre…

This study tests whether a 28- to 54-week program of weight-loss medication (semaglutide), a hormone-releasing IUD, diet, and exercise is safe and feasible before surgery in women with early endometrial cancer and a BMI of 40 or higher. Eighty participants will be randomly assign…

This phase 2 trial tests a drug called sacituzumab tirumotecan in people with neuroendocrine prostate cancer, a rare and aggressive form that has progressed after platinum-based chemotherapy. The drug is given by IV infusion three times per 42-day cycle. The study measures how ma…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This phase 2 trial is testing a new, intensive treatment plan for 28 people with advanced ovarian cancer. The approach combines chemotherapy given into the abdomen and vein, a special vaccine made from the patient's own immune cells, and the immunotherapy drug Keytruda. The goal …

This phase II trial tests whether combining elacestrant, a drug that lowers estrogen, with everolimus, which stops cancer cells from growing and cuts their blood supply, can control advanced or recurrent ER+ endometrial cancer. About 50 adults whose cancer has returned or spread …

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…

This Phase 3 trial compares an experimental drug, QLC5508, against the standard chemotherapy docetaxel in 700 men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy. The main goal is to see if QLC5508 delays cancer growth better than doce…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This early-stage trial tests a new drug, QLF4113, in about 140 men with metastatic castration-resistant prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to find a safe dose and check for side effects, while also looking for si…

This Phase 2 trial tests a combination of three drugs—camrelizumab, famitinib, and standard chemotherapy—in 54 women with recurrent or metastatic cervical cancer that cannot be treated with surgery or radiation. The goal is to see if the combo shrinks tumors and controls the dise…

This study tests a daily pill called zanzalintinib in men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Pluvicto. The goal is to see if the drug can delay cancer growth or shrinkage. About 30 participants will take …

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This study tests whether a self-applied cream (5-fluorouracil) after a heat procedure (thermal ablation) can clear HPV better than a placebo cream in 140 women with HIV in Kenya. Participants will use the cream every two weeks for 24 weeks and be followed for 48 weeks total. The …

This study looks at whether giving women living with HIV the option to collect their own HPV test samples at home or in their community, with help from health workers, increases how many get screened for cervical cancer. About 17,700 women will take part across multiple clinics. …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This phase II trial is testing whether adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery can help shrink tumors in women with early-stage cervical cancer (stages IB1-IB3). About 50 participants will receive the combination, then undergo conservative su…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This study tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to chemotherapy before standard chemoradiation can help people with locally advanced cervical cancer live longer without the disease getting worse. About 486 adults aged 18-75 with stage III-IV…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This study tests a new drug called zanzalitinib in people with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to soft tissues or organs. The goal is to see if the drug can slow or stop cancer growth. About 19 participants will receive…

This study tests whether adding a weight-loss shot (tirzepatide) to standard hormone therapy can better treat early-stage uterine cancer or pre-cancer in overweight women. About 30 participants will either get the standard progesterone IUD alone or the IUD plus tirzepatide. The g…

This study tests proton beam therapy for stage II seminoma, a testicular cancer that is highly curable. The goal is to see if this more targeted radiation can treat the cancer effectively while reducing long-term side effects and the risk of developing another cancer later in lif…

This early-phase study tests a shorter, more intense form of carbon-ion radiation for men with low- or intermediate-risk prostate cancer. Instead of the usual 12 sessions, patients receive just 6. The main goal is to check safety and side effects within 90 days. Up to 20 men will…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This phase 3 trial tests whether daily vitamin D supplements can improve immune function and quality of life in Black/West African men with prostate cancer who have low vitamin D levels. Researchers will compare men with localized disease to those with advanced cancer, tracking i…

This study tests a combination of two drugs, liposomal irinotecan and enlonstobart, in 30 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants receive treatment every tw…

This phase 2 trial tests whether adding mevrometostat to enzalutamide can slow cancer growth in 60 men with metastatic castration-resistant prostate cancer who have already been treated with similar drugs. Participants will take both drugs orally. The main goal is to see how long…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This early-stage study tests a special sheet called dMD-002 that helps repair nerves damaged during prostate removal surgery for prostate cancer. About 30 men will receive either the sheet or a placebo during their robot-assisted surgery. The goal is to see if it improves erectil…

This study will observe 500 women with ovarian, fallopian tube, or primary peritoneal cancer who are taking the drug senaparib. Researchers will track side effects and how well the drug controls the cancer in real-world conditions, outside of a strict clinical trial. The goal is …

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This phase 3 trial tests whether adding carboplatin to standard therapy can delay cancer growth in men with aggressive prostate cancer that has spread and has either a BRCA gene mutation or neuroendocrine features. About 330 participants will receive either standard care alone or…

This study tests a weekly, image-guided radiation therapy (SBRT) for men with very high-risk prostate cancer that may have spread to nearby lymph nodes. The treatment uses weekly CT or MRI scans to adapt the radiation dose precisely to the tumor. The main goals are to see if this…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This study looks at whether surgically removing uterine fibroids (myomectomy) before in vitro fertilization (IVF) helps women with infertility have a baby. About 792 women aged 20-39 with fibroids 4-6 cm that do not distort the uterine cavity will be randomly assigned to either h…

This study tests a new way to give radiation for prostate cancer using only 2 treatments instead of the usual 39. Doctors will use MRI scans to see how the tumor responds after the first dose, then adjust the second dose to target the cancer more precisely. The goal is to see if …

This early-stage trial tests a topical ointment called ACU-D1 for HPV-related vulvar and perianal lesions in people with HIV. Nine participants will apply the cream twice daily for 4 weeks. The main goal is to find the safest dose and see if the treatment can boost immune markers…

This trial tests whether a combination of a daily erectile medication, pelvic floor exercises, aerobic exercise, dietary advice, and mental health support can improve erectile function and urinary control in men after robot-assisted prostate removal for prostate cancer. Sixty-fou…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This study tests whether a traditional Chinese herbal formula (Tiaoshen Anti-cancer granules) combined with cognitive behavioral therapy for insomnia (CBT-I) can improve sleep and possibly extend survival in 360 women with advanced ovarian cancer. Participants will receive either…

This early-stage trial tests a new radioactive drug called 177Lu-FC516 in 13 men with advanced prostate cancer that has stopped responding to standard treatments. The drug is given every 6 weeks for up to 4 cycles. The main goals are to find the safest dose and check for side eff…

This early-phase study tests an experimental oral drug called KQB368 in 48 adults with advanced solid tumors (like lung, colorectal, or uterine cancer) that have a specific KRAS mutation (G12C or G12S). The main goals are to find a safe dose and see if the drug can shrink tumors.…

This study tests two experimental drugs, MRG003 and QL1706, together in people with cervical cancer that has returned or spread and no longer responds to standard chemotherapy. About 41 adults will receive the combination to see if it shrinks tumors. The goal is to control the di…

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This early-stage study tests two drugs, CKD-215 and D215, in 24 adults aged 19-75 with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to compare how the body processes each drug and check for side effects. Participants will receive both d…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This phase 2 trial is testing a daily pill called Inavolisib in about 48 people with advanced endometrial cancer that has a specific genetic change (PIK3CA mutation). The drug targets that mutation to try to shrink tumors or stop them from growing. Researchers will measure how ma…

This study tests a new approach called Bioblation, which combines a prostate biopsy with laser ablation in a single session under local anesthesia. It is for men with severe urinary symptoms and suspected low- to intermediate-risk prostate cancer. The goal is to see if this one-s…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This early-phase trial tests whether adding two drugs (darolutamide and homoharringtonine) to standard chemo and hormone therapy can more thoroughly clear high-risk prostate cancer before surgery. About 94 men will receive the combo for 7 weeks, then have their prostate removed t…

This pilot study will test a new device that uses pulsed field ablation (PFA) to treat localized prostate cancer in 50 men aged 45 or older. The goal is to see if the procedure is safe and effective at destroying cancer cells while minimizing damage to surrounding tissue. Partici…

This study tests a personalized radiation approach for men whose prostate cancer has returned after surgery. Using PSMA PET scans, doctors will give higher radiation doses to active cancer spots and lower doses to healthy areas, all in just 5 treatments over two weeks. The goal i…

This study tests whether daily adaptive radiotherapy (ART) can safely deliver shorter, more intense radiation treatments for prostate, endometrial, cervical, and rectal cancers. About 264 participants will be randomly assigned to standard radiation or ART, which uses daily imagin…

This study tests a new way to deliver radiotherapy for endometrial cancer after surgery. Using real-time MRI guidance, doctors can target radiation more accurately and reduce damage to nearby organs like the bowel and bladder. About 61 women will receive five high-dose sessions o…

This study compares two surgical approaches for early-stage endometrial cancer: laparoscopic staging (minimally invasive) and open staging laparotomy (traditional open surgery). Researchers will enroll 30 patients to see if laparoscopy is as safe and effective as open surgery, wi…

This study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while redu…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This early-stage trial tests a lab-grown penile tissue made from a man's own cells to repair severe, irreversible damage to the penis. Ten men aged 18-60 who have failed standard treatments will receive the implant. The main goal is to check safety, not effectiveness.

This study tests whether adding the experimental drug JSKN033 to standard chemotherapy (with or without bevacizumab) is safe and effective for people with advanced cervical cancer that has spread or come back. About 78 adults will take part. The goal is to control the disease and…

This study tests a new combination of two drugs (becotatug vedotin and pucotenlimab) in 20 adults with advanced penile cancer that has spread and is EGFR-positive. Participants must have failed or be unable to tolerate chemotherapy. The goal is to see if the treatment can shrink …

This study tests a combination of three drugs (Benmelstobart, Anlotinib, and low-dose Cyclophosphamide) in 40 women whose ovarian, fallopian tube, or peritoneal cancer has come back. The goal is to see if this mix can keep the cancer from growing for longer. Participants must be …

This study tests whether adding surgery and targeted radiation to a new hormone-blocking drug (rezvilutamide) can help men whose prostate cancer has spread to a few spots (oligometastatic). 300 men will be split into three groups: one gets the drug alone, one gets drug plus surge…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This early-stage trial tests a new oral drug called HLX97 in 138 people with advanced solid tumors (breast, prostate, or lung cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can slow tumor g…

This study tests a drug called darolutamide, with or without hormone therapy (ADT), given before surgery for high-risk localized prostate cancer. Sixty men will be split into two groups: one gets darolutamide alone, the other gets darolutamide plus ADT for 3-6 months before robot…

This phase 2 trial tests whether a peptide vaccine (NY-ESO-1) combined with an immunotherapy drug (toripalimab-tpzi) can prevent resistance to treatment in 24 women with stage III/IV ovarian cancer that no longer responds to platinum chemotherapy. The vaccine primes the immune sy…

This early study tests a personalized vaccine (YS247) made from a patient's own immune cells to fight a specific type of ovarian cancer (HRD-negative). Only 9 women who haven't been cured by standard therapy will take part. The main goal is to check safety, not yet to prove it wo…

This study tests whether giving a dye called Cytalux a few days before surgery works as well as giving it closer to the operation. The dye makes tumors glow under a special light, helping surgeons remove them more completely. About 106 adults with suspected lung cancer or confirm…

This study tests whether adding a glutaminase inhibitor (telaglenastat) to standard chemoradiation helps people with advanced cervical cancer live longer without the disease getting worse. About 42 adults with stage III–IVA cervical cancer will receive the drug alongside standard…

This phase 2 trial tests a drug called teverelix DP in 40 men with advanced prostate cancer. The drug works by blocking a hormone that tells the body to make testosterone, which can fuel cancer growth. The goal is to see if a specific dosing schedule can safely lower testosterone…

This early-stage trial is testing an experimental drug called GLR2037 in 65 men with metastatic prostate cancer that has spread to bones or soft tissues. The main goals are to check the drug's safety and how the body processes it. Participants will take GLR2037 daily in 28-day cy…

This study tests whether a combination of two drugs (camrelizumab and famitinib) can help prevent cervical cancer from returning after surgery. It involves 30 women with specific cancer types and PD-L1 positive tumors. The main goal is to see how many patients remain cancer-free …

This early-phase trial is testing an experimental drug called WSK-IM02 in 36 women with platinum-resistant recurrent ovarian cancer, a type that no longer responds to standard platinum chemotherapy. The drug is given as an injection into the abdomen. The main goal is to check saf…

This study compares a non-invasive ultrasound treatment (HIFU) to standard observation for low-grade cervical lesions (LSIL/CIN1) in 180 pre-menopausal women. Most of these lesions go away on their own, but the trial aims to see if HIFU can speed up clearance of the lesion and th…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests a new drug combination for women with recurrent ovarian cancer that still responds to platinum chemotherapy. The treatment includes an immunotherapy (iparomlimab/tuvonralimab) plus standard chemo, followed by a maintenance drug (olaparib). The goal is to see if t…

This phase II trial tests a drug called cadonilimab combined with radiation therapy for women with advanced cervical cancer who cannot receive standard chemotherapy due to age or health issues. The study will enroll 45 participants and measure how many have a complete response (n…

This study tests whether the drug rezvilutamide, combined with standard hormone therapy, can prevent high-risk prostate cancer from coming back after surgical removal. About 33 participants will take the pills and get injections for up to 2 years. The main goal is to see how many…

This trial is testing an experimental imaging agent called [⁶⁴Cu]Cu-RAX301, which is designed to bind to prostate cancer cells and show up on PET/CT scans. The study includes men with prostate cancer who are either about to have surgery to remove the prostate or who may have a re…

This pilot study investigates whether a PSMA PET scan, using an injected radiotracer, can detect clinically significant prostate cancer recurrence one year after focal HIFU treatment, compared with the standard MRI. About 30 men with prostate cancer who meet specific criteria wil…

This study is looking at whether a blood test called Galleri can help detect ovarian cancer early in people with BRCA1 or BRCA2 gene changes, who are at higher risk. Participants will give a blood sample and answer questionnaires about their experience. The study will also check …

This trial investigates whether Posluma, a PSMA-targeted PET scan, can accurately detect any remaining or returning prostate cancer about 12 months after focal therapy. Researchers will compare the scan results with MRI and biopsy data in 22 men with intermediate-risk, organ-conf…

This study tests a new AI framework called Cad-MMFF that combines clinical information, ultrasound, and MRI images to better detect clinically significant prostate cancer. The goal is to see if this approach can reduce unnecessary biopsies and safely limit the use of MRI. The stu…

This study is testing whether a new scoring system, called the Fusion CEMEP score, can safely guide prostate biopsy decisions. The goal is to see if men with suspected prostate cancer can skip the extra systematic biopsies and only have targeted biopsies based on MRI findings. Th…

This pilot study is testing whether a special PET/MRI scan using a radioactive tracer called 68Ga-PSMA-11 can better identify all areas of significant prostate cancer in men with localized disease. The goal is to improve selection for focal therapy, a treatment that targets only …

This trial tests whether a fluorescent dye called zopocianine can make prostate cancer cells glow under near-infrared light during surgery. Men with prostate cancer scheduled for prostatectomy receive a single dose of the dye before surgery. The goal is to see if the dye helps su…

This trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…

This study tests whether a new eye-tracking device called SONDA can accurately measure visual field loss in people with pituitary tumors. Standard visual field tests require patients to press a button when they see lights, which can be tiring and unreliable. The SONDA test instea…

This trial is testing whether a special PET scan (FTT-PET) and a blood test that looks for tumor DNA (ctDNA) can predict how well men with metastatic prostate cancer will respond to PARP inhibitor therapy. The study will enroll about 75 men whose cancers have certain genetic muta…

This study explores whether measuring radioactive counts from PSMA PET/CT-guided biopsy samples can instantly tell if a tissue core contains cancer. Researchers aim to find a cutoff value that reliably distinguishes cancerous from non-cancerous tissue, using standard pathology as…

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This study tests a new imaging technique that could help surgeons see if cancer has spread to lymph nodes during surgery for gynecologic cancers like ovarian, endometrial, cervical, and vulvar cancer. The method uses a special microscope to examine lymph node tissue right after i…

This study evaluates several experimental blood tests designed to detect ovarian cancer earlier. Researchers compare results from people with ovarian cancer to those without cancer to see how well the tests distinguish between the two. The tests look for specific changes in the b…

This study tests a new infrared fluorescence staining technique that could help doctors diagnose prostate cancer faster during a biopsy. The method is compared to the standard frozen section analysis and the gold-standard paraffin section. If successful, it may offer a quicker, m…

This study compares an AI algorithm to radiologists in reading prostate MRI scans to detect clinically significant prostate cancer. About 500 men with suspected prostate cancer will have their MRI read by both AI and a radiologist, and results will be compared. If the AI performs…

This study looks at whether a specialized blood test can detect tiny bits of cancer DNA in the blood of women with advanced ovarian cancer after they finish initial treatment. Researchers will follow 300 women for up to 3 years, taking blood samples at key times. The goal is to s…

This study compares robotic-assisted prostate biopsy to expert manual biopsy in 570 men with high BMI and suspicious MRI findings. The robot locks the needle in place to avoid hand tremors and improve accuracy. The main goal is to see if the robot detects more clinically signific…

This study tests a new PET/CT imaging agent called 68Ga-NYM032 in 232 men with suspected prostate cancer recurrence after initial treatment. Participants have rising PSA levels, and the scan aims to accurately locate any remaining cancer. The goal is to see how well the scan dete…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study will test a new urine test called My Prostate Score 2 (MPS2) combined with MRI to detect aggressive prostate cancer in men aged 50-75 with elevated PSA levels. The goal is to find only the cancers that need treatment and avoid unnecessary biopsies. The trial plans to e…

This phase 2 trial tests whether a new radioactive imaging agent, 61Cu-NU101, can detect prostate cancer spread as well as or better than the current standard, Pylarify. 34 men with confirmed prostate cancer and visible disease on a prior Pylarify scan will receive one dose of 61…

This study tests whether a special PET scan using fluciclovine can help doctors decide on treatment for men whose prostate cancer has returned after initial treatment, but whose standard PSMA PET scan was unclear or negative. About 142 men will receive the fluciclovine PET scan, …

This study tests a workshop led by peers and a Black GP to encourage Black men aged 45 and over to talk to their doctor about prostate cancer risk and get a PSA test. About 300 men from three UK regions will take part. Half attend the workshop right away, the other half wait six …

This study aims to develop a blood test that can accurately detect serious cervical lesions in women infected with HPV16 or HPV18, the high-risk types linked to cervical cancer. Researchers will collect blood samples and medical data from about 1,465 women across three hospitals …

This study compares a new, stronger 7 Tesla MRI to the standard 3 Tesla MRI for finding suspicious spots in the prostate. Researchers want to see if the stronger scanner can detect problems more clearly and possibly without using a contrast dye. About 200 men will get both scans …

This study will test a new blood test that looks for DNA changes to detect ovarian cancer, especially in early stages. Researchers will compare test results from 1,000 women with and without ovarian cancer to see how accurate it is. If it works well, it could lead to a simple scr…

The PRIORITY study is testing a new approach to diagnose cervical cancer earlier by combining self-sampling at home with digital colposcopy and telemedicine. Researchers will enroll 700 women aged 30 to 65 to see if this method is more accurate and faster than current care. The g…

This pilot study tests a new high-resolution PET-CT scan done during prostate cancer surgery to see if it can better detect cancer cells left behind or spread to lymph nodes. Ten men with high-risk prostate cancer will receive a special tracer injection before surgery, then get s…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This phase 2 trial will test whether a special PET scan using Flotufolastat F18 can accurately detect any remaining prostate cancer after focal therapy (like cryotherapy or HIFU). About 60 men with prostate cancer who haven't had prior treatment will get the scan before and after…

This study tests a special microscope that lets surgeons check for leftover cancer cells right after removing the prostate. It involves 20 men with prostate cancer who are already scheduled for surgery. The goal is to see if the microscope can accurately find cancer at the edges …

This study tests a new PET scanner built specifically to image the prostate. Researchers want to see if it can detect prostate cancer more clearly than standard whole-body PET scans. About 25 men with known or suspected prostate cancer will receive both scans, and the images will…

This study will compare a newer imaging method called 18F-PSMA PET/CT with the standard CT scan for prostate cancer patients. The goal is to see if the new scan is better at finding cancer initially, checking how well treatment is working, and detecting cancer that has come back.…

This study explores whether analyzing tumor DNA in urine can be a simple, non-invasive way to monitor prostate and bladder cancer. Researchers will collect urine samples from 25 patients at different treatment stages to see if the test can detect cancer mutations and track change…

This phase 2 trial tests a fluorescent dye called DGPR1008 that targets prostate cancer cells. Before robot-assisted prostate removal surgery, 18 men with prostate cancer will receive an injection of the dye. During surgery, a special camera will make cancer cells glow, helping s…

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This study tests whether practicing deep breathing exercises before surgery can lower the chance of postoperative delirium—a state of confusion and disorientation—in men undergoing robot-assisted prostate removal for prostate cancer. Half of the 50 participants will be taught a s…

This study tests whether it is practical and safe to remove the fallopian tubes during planned weight-loss (bariatric) surgery as a way to lower the risk of ovarian cancer. Many ovarian cancers are thought to start in the fallopian tubes, and removing them can reduce risk by abou…

This study tests whether taking low-dose aspirin can lower inflammation in the womb lining and help prevent endometrial cancer. It involves 25 postmenopausal women who have non-atrophic endometrial changes and pain. Participants will be randomly assigned to take aspirin or not, a…

This pilot study aims to see if offering self-collection kits for cervical cancer screening and HPV vaccination in emergency departments can reach women who have limited healthcare access. Researchers will enroll 100 women aged 18-65 and track how many participate and complete th…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether electroacupuncture (using mild electric pulses on needles) plus tiny thumbtack needles can prevent nerve damage caused by chemotherapy in people with early-stage cancer. About 278 patients with breast, stomach, bowel, lung, or ovarian cancer will receive …

This study will test if using two heat probes instead of one can better prevent cervical cancer in 300 women with HIV in Zimbabwe. The standard single-probe treatment often fails in these women. The goal is to see if the two-probe method is safe, acceptable, and more effective at…

This study tests whether using two probes during a heat-based treatment (thermal ablation) works better than the usual one-probe method to prevent cervical cancer in women living with HIV. About 200 women aged 25-49 with HIV and cervical precancer will be enrolled. The goal is to…

This study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…

This study tests whether removing the fallopian tubes at the same time as gallbladder surgery is safe and practical. Ovarian cancer often starts in the fallopian tubes, so removing them may prevent it. The trial will enroll 240 women aged 35 and older to see if the extra procedur…

This study checks if testing for high-risk HPV before a subtotal hysterectomy can help prevent cervical cancer. About 300 women scheduled for this surgery will get an HPV test; if positive, they will have a cone biopsy to remove any precancerous cells during the same operation. T…

This study will test if giving a 9-valent HPV vaccine to women who previously received the bivalent HPV vaccine is safe and boosts their immune response. Researchers will enroll 360 healthy women aged 18-45 and compare two different dosing schedules (two doses vs. three doses) ag…

This study tests whether a cream called triethanolamine (Trolamine) can prevent or reduce vaginal inflammation caused by radiation therapy in cervical cancer patients. About 238 women will either use the cream daily during radiotherapy plus routine care, or receive routine care a…

This study tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) can prevent postoperative delirium in elderly patients undergoing urological surgery. Researchers will apply TMS to the left frontal lobe during anesthesia and monit…

This study tests a new two-step preventive surgery for women with gene mutations (like BRCA1) that raise their risk of ovarian cancer. Instead of removing both ovaries and fallopian tubes at once, the first step removes only the fimbria (the end of the fallopian tube), and the ov…

This study tests whether using two heat probes instead of one can better prevent cervical cancer in women living with HIV, who face a much higher risk. Researchers will enroll 300 women in Kenya to see if the two-probe method is safe, acceptable, and more effective at clearing HP…

This trial tests whether an artificial intelligence chatbot can help men with prostate cancer better understand radiation therapy. Participants will use a plain-language chatbot alongside standard education from their care team. Researchers will measure changes in patients' confi…

This pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…

This study tests whether adding estrogen to standard prostate cancer treatment can improve quality of life for 60 men with metastatic hormone-sensitive prostate cancer. Standard therapy often causes hot flashes and other side effects by lowering estrogen. The study compares estro…

This phase 2 trial tests whether a low dose of naltrexone (LDN) can reduce fatigue in men with prostate cancer who are on hormone therapy (ADT). The study will enroll 60 participants and measure fatigue, quality of life, and safety. It is not yet recruiting.

This study tests whether adding telehealth sex therapy to standard pelvic floor physical therapy helps men recover urinary and sexual function after prostate cancer treatment. All participants receive pelvic floor therapy and education on using a vacuum erection device. Half are …

This pilot study tests whether high-intensity interval training (HIIT) before prostate removal surgery can improve recovery and reduce anxiety. Men scheduled for radical prostatectomy will do vigorous exercise for about 60 minutes per week for at least four weeks before their ope…

This study tests whether an AI-powered program can help older adults with serious illnesses like cancer or heart disease manage emotional distress. Participants receive short videos and daily check-ins from a chatbot that teaches practical coping skills, all from their own phone.…

This trial tests a supportive care program called E-MOTE, delivered by an AI-assisted robot during hospital stays and a mobile app after discharge, for women newly diagnosed with gynecologic cancer who are undergoing surgery. The program includes emotional assessments, empathetic…

This trial tests whether mind-body practices like breathwork, meditation, and gentle yoga can improve quality of life, stress, and sleep in people who have recently finished cancer treatment. Participants will practice these techniques weekly for six weeks while wearing an activi…

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…

This study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…

This trial tests an 8-week eHealth program called eMindExCare that combines mindfulness practices with home-based aerobic and resistance exercises for prostate cancer patients undergoing active treatment. The study aims to see if the program is feasible and acceptable, and whethe…

This study tests whether watching storytelling videos and writing or talking about personal experiences can reduce stigma and improve quality of life for women living with both cervical cancer and HIV in Zambia. Participants are randomly assigned to different combinations of stor…

This trial tests whether a wearable device that delivers a cooling sensation on the wrist can reduce the burden of hot flashes in men with prostate cancer who are on androgen deprivation therapy (ADT). About 66 participants will be randomly assigned to use the device right away o…

This trial investigates whether acupuncture can help women who have trouble urinating after a radical hysterectomy for cervical cancer. Participants receive either real acupuncture or a sham version (using non-penetrating needles) alongside standard care with a catheter and medic…

This study tests whether acupuncture can reduce hot flashes in 40 men with prostate cancer who are on hormone therapy. Hot flashes are a common side effect that can disrupt sleep and daily life. Participants will receive real or sham acupuncture, and researchers will track change…

This trial investigates whether a supervised program of aerobic and strength training can improve quality of life, heart function, and body composition in men with prostate cancer who are receiving androgen deprivation therapy (hormone therapy). The study involves 46 men aged 40 …

This pilot study tests a communication skills training program called Starting the Conversation for prostate cancer patients who are bothered by sexual problems. About 100 men will either receive the training or a general health education program. The goal is to see if the traini…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This study compares two types of radiation therapy for prostate cancer: one that boosts the whole prostate gland and one that boosts only the main tumor. About 186 men will be randomly assigned to one of the two treatments. The goal is to see which approach causes fewer urinary a…

This pilot study tests whether a device called Flyte can help improve urinary incontinence in women who had radiation therapy for endometrial or cervical cancer. The Flyte device is used at home and delivers gentle vibrations while the user does Kegel exercises. The study will ch…

This study tests whether adding cyclobenzaprine, a muscle relaxant, to standard pain medicines (ibuprofen, acetaminophen, and short-term narcotics) improves pain control and reduces narcotic use after minimally invasive hysterectomy. About 36 women undergoing laparoscopic hystere…

This study tests a web-based program designed to help caregivers of prostate cancer patients deal with uncertainty and reduce the burden of caregiving. The program is based on a theory about how people handle uncertainty in illness. Researchers will measure changes in caregivers'…

This study tests whether taking high doses of vitamin E and CoQ10 daily for 90 days can reduce chronic side effects from pelvic radiation in people treated for prostate, uterine, cervical, or anal cancer. Researchers will monitor safety, side effects, and quality of life in 200 a…

This pilot trial tests whether adding emotional support to a cancer information website helps young adults (ages 20-39) with thyroid, melanoma, or testicular cancer feel less worried and distressed. 142 participants will either get general cancer info or the same info plus person…

This study looks at whether a prehabilitation program—including physical therapy, dietary advice, and emotional support—given before major cancer surgery can reduce deaths and serious complications within 30 days after the operation. About 180 adults with cancers of the pancreas,…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests whether a 12-week exercise program, delivered via Zoom, is practical and helpful for older adults (65+) with cancer who live in rural areas. Participants will do two supervised exercise sessions per week. The goal is to see if the program improves quality of life…

This study tests whether a single hypnosis session during chemotherapy can reduce anxiety and other side effects like nausea in young people with cancer. It includes 70 participants aged 15-49 with sarcoma, germ cell tumors, or breast cancer. Researchers will compare anxiety leve…

This study looks at whether teaching pelvic floor muscle exercises before and after prostate removal surgery can help men control urine leakage and feel better day-to-day. Ten men who have surgery for prostate cancer will learn these exercises from nurses. The goal is to see if t…

This pilot trial will test whether a prehabilitation program (exercise, protein drinks, breathing exercises, and coaching) is feasible for women awaiting ovarian cancer surgery. It compares in-person delivery, remote delivery via a web app, and standard education-only care. The s…

This pilot study tests whether a physiatry-led prehabilitation program—including exercise, nutrition, and mind-body practices—can help women with advanced gynecologic cancer stay stronger before surgery. Twenty-five participants will follow the program during their neoadjuvant tr…

This study tests whether cauterizing the uterine artery at its origin before removing the uterus via laparoscopy reduces blood loss and surgery time compared to the standard technique. It will involve 44 women over 35 with non-cancerous conditions like fibroids or abnormal bleedi…

This study tests if a newer, shorter course of radiation therapy (MH-ART) is as good as the standard longer course (CF-IMRT) for women who have had surgery for cervical or endometrial cancer. The goal is to see if the new approach causes fewer side effects and improves quality of…

This study tests if fezolinetant can reduce hot flashes in men receiving hormone therapy for prostate cancer. About 54 men will take either the drug or a placebo, and track their hot flash severity and quality of life. The goal is to ease this common side effect without affecting…

This study tests whether a special care plan called Enhanced Recovery After Surgery (ERAS) helps women recover faster after a hysterectomy. About 78 women will be randomly assigned to either ERAS or standard care. The goal is to see if ERAS shortens hospital stays and reduces pai…

This study develops and tests a support program for cancer survivors who worry about their cancer returning. 150 adults who finished treatment for breast, head and neck, colon-rectal, or prostate cancer will join. Depending on their level of fear, they will receive education, psy…

This trial tests a new single-channel bag used during keyhole surgery to remove uterine fibroids. The bag holds the fibroid while it is cut into smaller pieces, and the goal is to see if it makes the surgery faster and simpler than the current two-channel bag. About 78 women aged…

This study compares two types of prehabilitation (exercise, nutrition, and psychological support) for 225 women with advanced ovarian cancer. One group starts prehab early during chemotherapy, while the other starts just before surgery. The goal is to see if early prehab reduces …

This study tests a device called TUNES, which delivers gentle electrical stimulation through a menstrual disc to nerves near the uterus. The goal is to see if it can reduce pain and the need for pain medication in 60 women after uterine fibroid embolization. Participants will be …

This study tests whether a supervised exercise program can help women who have had breast or gynecological cancer and now suffer from muscle loss (sarcopenia). The 78 participants will do resistance, aerobic, balance, and stretching exercises. Researchers will measure changes in …

This study tests whether an 8-week online mindfulness program can improve hope, emotional coping, quality of life, and psychological well-being in women with gynecological cancer. About 96 women currently receiving treatment will be randomly assigned to either the mindfulness pro…

This study looks at whether bringing in palliative care early during an unplanned hospital stay can reduce aggressive treatments at the end of life for people with advanced cancer. About 493 adults with metastatic digestive, gynecological, ENT, or sarcoma cancers will be randomly…

This study tests whether a new way of planning radiation—sparing the pelvic and lower spine bones—can lower the risk of severe blood-related side effects in women with advanced cervical cancer. About 72 participants will receive standard chemoradiotherapy, but half will have thei…

This study follows 130 men with unfavorable intermediate-risk prostate cancer to see how a combination of targeted radiation (SBRT) and 6 months of hormone therapy (ADT) impacts their sexual function. Researchers measure erectile function before treatment and again after 24 month…

This study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…

This study aims to create new laboratory models of ovarian cancer that no longer respond to standard platinum-based chemotherapy or PARP inhibitors. Researchers will take tumor tissue from patients with resistant disease and grow it in mice and in the lab to mimic real clinical c…

This study aims to understand how migration history and social factors affect the quality of life of Black immigrant men from Sub-Saharan Africa and the Caribbean who have been diagnosed with prostate cancer. Researchers will interview 40 men to learn about their experiences and …

This study aims to develop an online educational tool for women diagnosed with endometrial cancer. Participants will use a website to access educational content, complete surveys, and provide feedback on its usability. The goal is to create a resource that can be made widely avai…

This pilot trial tests whether a risk calculator designed for Nigerian men can help primary care providers better identify those with clinically significant prostate cancer. Researchers will train healthcare workers at community hospitals and then support them in using the tool f…

This trial explores whether a whole-body bone scan (SPECT/CT) taken in the treatment position can help doctors plan stereotactic radiotherapy more precisely for prostate cancer that has spread to the bones. Thirty patients will receive the scan in addition to standard imaging, an…

This study looks at how a special program, called the Geriatric Surgery Verification Program, works at the James Cancer Hospital. The program helps doctors and nurses better care for patients aged 65 and older who need cancer surgery. It includes checking for age-related issues l…

This study will test whether a special MRI scan (CSE-MRI) can accurately measure active bone marrow in men with metastatic prostate cancer, compared to a standard PET scan using a radioactive tracer (FLT). Fifteen participants will receive both scans at the same time using a comb…

This study looks at whether artificial intelligence and detailed molecular analysis can help predict how high-grade serous ovarian cancer will behave after surgery. Researchers will analyze tumor images, genetic data, and patient records from 1,300 women to build a model that for…

This study follows women aged 70 and older with ovarian cancer to understand why some experience cognitive decline or delirium during treatment. Researchers will track memory, thinking skills, frailty, and quality of life over 12 months, and analyze blood samples for markers of b…

This study looks at how a short, home-based high-intensity workout affects steroid hormones in men with low-grade prostate cancer who are on active surveillance. About 49 men will do one supervised bodyweight HIIT session and provide saliva samples. The goal is to see if the exer…

This study looks at how certain cancers develop in people with HIV and what factors might increase their risk. Researchers will analyze medical data from 1,000 HIV-positive adults to track which types of cancer occur most often and why. The goal is to improve early detection and …

This study looks at postmenopausal women who have a thickened uterine lining (endometrium) found by chance but have no symptoms like bleeding. Researchers will use a tiny camera (hysteroscopy) to view the lining and take tissue samples to compare the camera findings with lab resu…

This study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study looks at men with localized prostate cancer who had robot-assisted surgery to remove the prostate. The goal is to find which factors—like PSA levels, tumor grade, or MRI results—best predict whether the cancer will come back (called biochemical recurrence). Researchers…

This study will include about 2,748 people with breast, gynecologic, or pancreatic cancer. Researchers want to see if adding patient-reported outcomes—like symptoms, preferences, and travel distance—to tumor board discussions helps doctors make better treatment decisions. The goa…

This study explores whether artificial intelligence can help perform high-field whole-body MRI scans faster while keeping image quality high. Researchers will compare standard MRI sequences with AI-accelerated versions in 600 adults undergoing screening for prostate, lung, or vas…

This study looks at whether taking bicalutamide for two weeks can make PSMA PET/CT scans better at finding small amounts of prostate cancer that standard scans might miss. It involves 20 men with recurrent prostate cancer and very low PSA levels. Participants are randomly assigne…

This study looks at whether pieces of tumor DNA and HPV DNA circulating in the blood can predict if cervical cancer will return after successful first-line treatment. Researchers will collect blood samples over time from 60 patients whose cancer has gone into complete remission. …

This study observes how well a combination of two drugs, olaparib and abiraterone, works as a first treatment for men with metastatic castration-resistant prostate cancer who have already tried other hormone therapies. Researchers will track how long patients stay on the treatmen…

This study looks at how common stigma is for breast and cervical cancer patients, caregivers, and community health workers in Rwanda. It also tests a program called RISE that includes resilience training, support groups, and videos of cancer survivors to see if it can reduce stig…

This study tests whether the Stockholm3 blood test can accurately detect when low-risk prostate cancer becomes more aggressive in men who are closely monitored instead of treated immediately. Researchers will enroll 350 men on active surveillance to see if the test can reduce the…

This study looks at how to safely place a breathing tube in people with acromegaly, a condition that can cause changes in the face and airway. It compares two methods: direct laryngoscopy and video laryngoscopy. The goal is to find which method gives a better view of the airway a…

This study will send different types of WhatsApp messages to 235,000 people in Chile who are due for cancer or chronic disease screenings. Researchers want to see if the way a message is worded (basic, risk-focused, or peace-of-mind) and whether it mentions one test or both tests…

This study tests whether injecting a radioactive tracer directly into the prostate artery improves imaging compared to standard arm injection in 10 men with high-risk prostate cancer. The goal is to see if this method gives clearer pictures and helps predict the right radiation d…

This study will look at whether SPECT scans taken after Lu-PSMA therapy can help predict how well patients with metastatic castration-resistant prostate cancer (mCRPC) are doing. Researchers will measure tumor activity and volume on the scans and compare them to standard PET-base…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study will develop and test a free, cloud-based platform to educate women aged 18-45 with early-stage gynecologic cancer about fertility preservation options. Researchers will compare awareness, knowledge, and attitudes between a group using the platform and a group receivin…

This study looks at how doctors in tumor board meetings work together when discussing ovarian and uterine cancer cases. About 400 physicians will fill out surveys after each meeting to measure things like communication, teamwork, and decision-making. The goal is to understand wha…

This study looks at how Black and Hispanic adults in the U.S. feel about online information on prostate cancer. Participants will view a video or text post about the disease and then fill out a short survey. The goal is to understand trust and emotional reactions to online health…

This study looks at how to make cervical cancer screening easier for women with HIV, who are at higher risk for this cancer. Researchers will talk to patients and doctors to find out what gets in the way of screening and follow-up care. They will also explore using HPV self-testi…

This study will follow 100 people with advanced cervical cancer who are getting radiation and chemo. Researchers want to see if checking for HPV and other markers in the blood and cervix can better predict if the cancer will come back. The goal is to find recurrences earlier and …

This study looks at the best way to help prostate cancer survivors learn about and get genetic testing for inherited cancer risks. About 500 participants will be randomly assigned to a digital guide, a printed guide, or standard care. Researchers will track who requests testing a…

This study looks at whether a web-based education program can improve women's attitudes and beliefs about HPV testing, which is key for preventing cervical cancer. About 120 women aged 18-60 will take part, with half receiving the online education and the other half getting stand…

This study looks at whether giving patients clear, standardized instructions before and after pituitary surgery can improve their recovery. Researchers will compare hospital stay length, complication rates, and unplanned readmissions in 102 adults having elective surgery. The goa…

This study will compare two types of robot-assisted surgery for prostate or kidney cancer: single-port (one small incision) and multi-port (several incisions). Researchers will track 376 adults to see which approach leads to a shorter hospital stay and better recovery. The study …

This study will survey about 950 men who stored sperm at a French fertility center before cancer treatment between 2010 and 2024. Researchers want to know how many later became fathers, whether naturally or with medical help, and if they used their frozen sperm. The goal is to be…

This study compares two minimally invasive surgical methods for early-stage endometrial cancer: standard laparoscopy (small abdominal cuts) and vNOTES (surgery through the vagina with no visible scars). Researchers will enroll 160 women to see how well each method finds sentinel …

This study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …

This study follows 250 gynecologic cancer patients and their informal caregivers over 6 months. Researchers will use surveys to track caregiver distress and unmet needs. The goal is to understand what caregivers go through and find ways to better support them.

This study tests whether a dye called indocyanine green can help surgeons find cancer spread in early ovarian cancer. About 30 women will receive the dye during surgery to see if it can identify affected lymph nodes. If it works, it may reduce the need for removing many lymph nod…

This study looks at how a person's body composition—like muscle and fat levels—affects the radiation dose delivered to tumors and healthy organs during a targeted therapy for advanced prostate cancer. About 100 men with a specific type of prostate cancer will receive the standard…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study will compare how much pain men expect versus actually feel during two common prostate biopsy methods: transrectal and transperineal. About 200 men having their first prostate biopsy will rate their pain before and after the procedure. The goal is to help doctors choose…

This study will ask 50 people aged 35 and older with abnormal uterine bleeding to collect daily urine samples and track their bleeding at home for several months. Researchers will use a home monitor to measure hormone levels and see if certain patterns are linked to uterine cance…

This study looks at whether the LASMAR scoring system can predict how well hysteroscopic myomectomy works for women with submucous fibroids. Researchers will check if the score matches surgery time, number of sessions, fluid use, and complications. The goal is to help doctors pla…

This study tests a plastic scintillation detector that can monitor radiation dose and source position in real time during brachytherapy for prostate and gynecologic cancers. The goal is to see if the device can be used without disrupting the treatment workflow. If it works, it co…

This study looks at better ways to screen for HPV and prevent cervical cancer in women living with HIV. Researchers will test a new method that identifies specific HPV types and viral load. The goal is to see if this approach is practical for a larger future study. About 750 wome…

This study tests a digital tool called TRANSCEND-XR that uses extended reality (like virtual reality) to help adolescents and young adults who have finished treatment for testicular cancer. The tool aims to teach them about long-term side effects, when to see a doctor, and how to…

This early-phase trial tests an artificial intelligence system that watches live video from pituitary tumor surgeries performed through the nose. The AI identifies anatomy, instruments, and surgical steps, displaying its analysis on tablets for the surgical team (not the lead sur…

This study aims to learn about genetic changes in metastatic prostate cancer and how they affect patient outcomes. Researchers will collect and analyze tissue and blood samples from 100 adults in Brazil who are receiving standard palliative therapy. The goal is to better understa…

This study will follow 700 men with high-risk localized or metastatic prostate cancer to collect detailed information on how they are treated in everyday practice. Researchers will track treatments, side effects, quality of life, and disease progression over time. The goal is to …

This study will test whether ChatGPT, an artificial intelligence chatbot, can help men better understand their prostate cancer diagnosis. Fifty men who recently had a prostate biopsy will use the chatbot to review their pathology results. Researchers will measure how accurately p…

This study looks at whether a blood test can predict how well certain cancer drugs (PARP inhibitors) work in people with advanced breast, prostate, ovarian, or pancreatic cancer. Researchers will collect blood and tumor samples from 300 adults to analyze cancer cells and their DN…

This study tests whether a special education program can increase breast and cervical cancer screening among visually impaired women. About 74 women over age 40 will receive training on cancer risks and how to schedule screenings. Researchers will check if screening rates and kno…

This study looks at two different gas flow levels (low vs. minimal) for the anesthesia drug sevoflurane during robot-assisted prostate cancer surgery. The goal is to see which flow rate better maintains healthy breathing and oxygen levels during the procedure. About 70 men having…

The BALANCE study is a research project that asks Black and mixed-ancestry men with prostate cancer about their quality of life after treatment. Researchers want to learn how different treatments affect physical health, mental health, and daily life in these communities. By colle…

This study follows 42 women with HPV-positive pelvic cancer (cervix, vagina, vulva, or anus) to understand how radiotherapy, with or without surgery, affects their sexual quality of life. Participants complete questionnaires about sexual function and emotional distress over time.…

This phase 2 trial is testing four different doses of enzalutamide (40, 80, 120, and 160 mg) in men aged 75 and older with advanced prostate cancer. The goal is to see how drug levels in the blood differ between older and younger patients, and to find the safest and most effectiv…

This study compares laparoscopic (keyhole) hysterectomy to traditional open abdominal hysterectomy in women aged 35-65 with benign gynecologic conditions. The main goal is to see which approach leads to a shorter hospital stay. The trial takes place in a low-resource setting, whe…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study will observe how the drug lutetium-177 vipivotide tetraxetan is actually used in patients with metastatic prostate cancer. Researchers will collect data from medical records across multiple countries, using AI to analyze treatment patterns and outcomes. The goal is to …

This study uses an anonymous online survey to ask 200 women with gynecologic cancers whether they would be interested in receiving long chemotherapy infusions at night instead of during the day. The goal is to understand patient preferences and potential barriers. No treatment is…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study is testing a new questionnaire (called the QLQ-OV39) to see how well it measures quality of life in people with ovarian cancer. About 50 adults with early or advanced ovarian cancer will fill out the questionnaire and give feedback. The goal is to make sure the questio…

This study aims to see if a special device called a U-Cup bioreactor can predict how well standard chemotherapy will work in women with high-grade ovarian cancer. Researchers will take tumor samples from 120 patients before treatment and test them in the lab. The goal is to find …